POTS is a syndrome, not a disease
Satish Raj's 2006 review in the Indian Pacing and Electrophysiology Journal has been cited in over 312 subsequent papers. It is not a study — it is a conceptual reframe that changed how the research community thinks about postural tachycardia. Its argument is straightforward and its implications are still not fully realized in clinical practice: POTS is a syndrome, not a disease. The tachycardia that defines it is the measurable output of a compensatory system doing its job. Multiple different upstream failures can produce the same output. The label identifies the compensation, not the failure that triggered it.
What the Diagnostic Criterion Actually Measures
The POTS diagnostic criterion — a sustained heart rate rise of 30 beats per minute or more within 10 minutes of standing, without orthostatic hypotension, accompanied by chronic orthostatic symptoms — was developed to identify patients with significant upright intolerance that did not meet the more severe threshold of syncope or orthostatic hypotension. In younger patients, the threshold is sometimes applied at 40 bpm or more to account for age-related differences in baseline sympathetic tone.
The criterion does what it was designed to do: it identifies a measurable physiological pattern. But the pattern is a compensatory response, and compensation can emerge from multiple different system failures. Raj's review catalogs these: reduced circulating blood volume (hypovolemia), excessive peripheral venous pooling driven by impaired vasoconstriction, small fiber neuropathy that has disrupted the autonomic innervation of peripheral blood vessels, hyperadrenergic states in which the sympathetic nervous system is operating in overdrive, and deconditioning that has reduced the cardiovascular system's reserve capacity for orthostatic stress.
In each of these scenarios, the final common pathway is the same. Venous return to the heart is insufficient when the patient stands. The heart compensates by increasing rate. The rate crosses 30 bpm. POTS is diagnosed. The mechanism that drove the sequence may be completely different from one patient to the next.
How the Same Compensation Produces Different Clinical Pictures
The upstream diversity of POTS is not merely academic. It produces recognizably different clinical presentations that carry information about which mechanism is at work.
Hypovolemic POTS patients typically have low plasma volume, measurable on nuclear medicine testing. They may improve substantially with high-sodium diet, aggressive fluid intake, and volume-expanding medications like fludrocortisone. Their symptoms often improve when lying flat and worsen rapidly on standing because the gravity-driven redistribution of an already small blood volume is the primary mechanical stress.
Neuropathic POTS patients have peripheral autonomic neuropathy — specifically, loss or dysfunction of the small nerve fibers that regulate vasoconstriction in the lower extremities. When these fibers fail, blood pools in the legs and splanchnic vasculature during standing. The failure is not in blood volume per se but in the nervous system's ability to prevent pooling. Skin punch biopsy demonstrating reduced intraepidermal nerve fiber density below the ankle can identify these patients. Compression garments and agents that promote peripheral vasoconstriction address the mechanical problem that vasoconstriction failure is creating.
Hyperadrenergic POTS presents with a clinical picture that is often mistaken for anxiety: palpitations, tremor, sweating, and blood pressure that may actually rise rather than fall on standing. Standing plasma norepinephrine at or above 600 pg/mL is the characteristic finding. These patients have an overactive sympathetic system, not an underactive one. Rate-reducing sympatholytic medications may be more appropriate here than in other subtypes, because the problem is excess sympathetic output, not inadequate compensatory response.
Deconditioned POTS reflects a cardiovascular system that has lost its adaptive reserve. Cardiac stroke volume falls with sustained inactivity. Blood volume decreases. The body's capacity to autoregulate orthostatic stress diminishes. Athletes who have had to stop training for weeks due to illness, or patients who have spent extended time bedbound, may develop this pattern. Exercise rehabilitation — carefully structured to avoid worsening orthostatic symptoms through upright exertion — is the primary treatment. The tachycardia here resolves as the cardiovascular system regains capacity.
Why Treating the Compensation Produces Variable Results
The standard treatment cascade for POTS in many clinical settings involves a combination of lifestyle measures (increased salt and fluid, compression garments), rate-controlling medications (beta blockers, ivabradine), and sometimes volume-expanding agents (fludrocortisone, desmopressin). These interventions were developed across a patient population that, based on the Raj framework, contains multiple mechanistically distinct subtypes mixed together.
This matters because each intervention has a mechanism, and that mechanism fits some subtypes and not others. Beta blockers slow the heart. In a patient whose tachycardia is the compensatory mechanism keeping cerebral blood flow adequate during standing, slowing the heart reduces the compensation. The patient's heart rate improves on paper. Their brain fog, fatigue, and cognitive impairment — driven by inadequate cerebral perfusion when upright — may worsen or stay the same. The metric improved. The physiology did not.
Fludrocortisone expands plasma volume. In a hypovolemic patient, this addresses the deficit. In a neuropathic patient whose problem is vasoconstriction failure, adding volume does not fix the fact that blood still pools in the lower extremities when standing. The expanded volume pools more thoroughly. The mechanism is not addressed. The Raj review predicts this variability directly: if the same intervention is applied across mechanistically different patients, results will be heterogeneous, and that heterogeneity does not reflect the failure of an intervention category — it reflects the failure to match the intervention to the subtype.
What a Syndrome Diagnosis Should Require
Raj's 2006 framing implies a clinical standard that has still not been widely implemented. If POTS is a syndrome rather than a disease, then diagnosing POTS is the beginning of a clinical workup, not the conclusion of one. The diagnosis identifies that the orthostatic tachycardic pattern is present. It does not identify which upstream mechanism is producing it.
The additional workup needed to answer that question includes plasma volume measurement to characterize hypovolemia, skin punch biopsy for neuropathic involvement, standing plasma norepinephrine for hyperadrenergic identification, and a careful history and cardiovascular assessment for deconditioning. This is not an exhaustive or expensive workup. The information it provides changes the treatment logic for each identified subtype.
Most patients with POTS have not had this workup. Most have been diagnosed by tilt table or active stand testing and sent into a standard protocol. What the Raj framework tells those patients is that their diagnosis describes a measurable output without characterizing the system failure that is producing it. The failure matters. The treatment that addresses it depends on knowing what it is.
The 2006 paper was foundational enough to be cited hundreds of times in the decades since. The gap between its framing and current clinical practice is not a knowledge gap in the research literature. It is a translation gap between what the science established and what most patients encounter when they walk into a specialist's office with a tachycardia on a tilt table and a stack of normal prior test results.